Sorafenib tosylate

IUPAC name

4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N methylpyridine-2-carboxamide;4-methylbenzenesulfonic acid



Molecular Weight

637.0 g·mol−1

Molecular Formula


Granule:    Available

Ready to press ‏þ

Ready to fill o

Mechanism Of Action:

  • Sorafenib has demonstrated decreased tumor cell proliferation in vitro.
  • It was shown to inhibit multiple intracellular (c-CRAF, BRAF, and mutant BRAF) and cell surface kinases (KIT, FLT-3, RET, RET/PTC, VEGFR-1, VEGFR-2, VEGFR-3, and PDGFR–ß). Several of these kinases are thought to be involved in tumor cell signaling, angiogenesis, and apoptosis.
  • It also has showed inhibition of tumor growth and decreasing of tumor apoptosis in models of hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and differentiated thyroid cancer (DTC).


  • The treatment of patients with unresectable hepatocellular carcinoma (HCC)
  • The treatment of patients with advanced renal cell carcinoma (RCC).
  •  The treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment.